PharmacoLearnIt’s Important to Know!

Daily Pharma News - 28 September 2026

CDSCO tightens scrutiny of drugs containing narcotic, psychotropic substances

India's Central Drugs Standard Control Organisation is reviewing the regulatory framework to stop the illegal diversion of pharmaceutical preparations containing narcotic and psychotropic substances. The move follows directions from the June meeting of the Narco Coordination Centre (NCORD), chaired by the Union Home Minister, which tasked the regulator with identifying and closing gaps by March 2027; the matter is now before the Drugs Consultative Committee.

For pharmacy students, this is a live case study in regulatory science and the interface between drug regulation and enforcement. Narcotic-containing formulations - from codeine-based cough syrups to opioid combinations - sit at the intersection of the Drugs and Cosmetics Act and the NDPS Act, and the forthcoming framework will likely mean tighter licensing, record-keeping, and dispensing norms that pharmacists will have to implement on the ground.

NovaLead's repurposed Esmolol gel gets CDSCO nod for diabetic foot ulcer

CDSCO has approved NovaLead Pharma's patented topical gel of Esmolol hydrochloride for the treatment of diabetic foot ulcer (DFU) in the Indian market. DFU is a major unmet need - it causes roughly 100,000 amputations every year in India - and the approval was based on a randomized, double-blind Phase 3 trial against standard of care. Notably, the development was part-funded by BIRAC, the government's biotechnology industry research body.

Esmolol is a classic beta-1 selective blocker known for decades as an injectable anti-arrhythmic, and this is a textbook example of drug repurposing: reformulating a well-characterized molecule into a topical gel for wound healing. Pharmacy students should note the regulatory significance too - repurposed drugs can move through approval faster because their systemic safety profiles are already established, and public-private support through BIRAC shows how government funding is de-risking Indian pharmaceutical innovation.

Sanofi India faces Rs 23.74 crore GST demand from Bengaluru tax office

Sanofi India has received a show-cause notice dated September 25 from the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, under the Karnataka GST Act, alleging excess Input Tax Credit claimed for FY 2022-23. The proposed demand totals Rs 23.74 crore - Rs 14.43 crore in tax plus Rs 9.31 crore in interest - though the company has stated it expects no adverse financial impact.

While this is a tax-compliance story rather than a drug story, it belongs in every pharmacist's education: pharmaceutical companies operate inside complex fiscal regulation, and Input Tax Credit disputes directly affect pricing and compliance departments. Understanding GST mechanics is increasingly part of hospital and retail pharmacy administration, so treat stories like this as real-world pharmacoeconomics.

IASO Bio reports first-in-human data for in vivo BCMA CAR-T IASO206

At the 2026 meeting of the International Myeloma Society, China's IASO Bio presented Phase 1 data (September 27, 2026) for IASO206, an in vivo BCMA-targeted CAR-T therapy. Instead of the conventional ex vivo process - extracting a patient's T cells, engineering them in a lab, and re-infusing them - IASO206 generates CAR-T cells inside the patient's own body through a single intravenous infusion, with no lymphodepleting chemotherapy required. The results: 90% objective response and 90% minimal residual disease (MRD) negativity in relapsed/refractory multiple myeloma, rising to 100% in the high-dose cohort.

This is a genuinely exciting advance for cell therapy. Conventional CAR-T is powerful but logistically heavy and expensive - it demands cell-processing labs, weeks of waiting, and harsh conditioning chemotherapy. An off-the-shelf-style in vivo CAR-T that skips lymphodepletion could dramatically widen access, which matters enormously for countries like India building CAR-T capacity. Pharmacy students should track BCMA as a target (it is central to modern multiple myeloma therapy) and understand MRD negativity as the deep-response benchmark in haematological malignancies.

Russia approves rules for circulation of personalized biotech drugs

The Russian government has approved rules governing the circulation of personalized biotechnological drugs (BTLP) - medicines manufactured in medical organizations from a patient's own genetic material. Clinics producing these patient-specific therapies will need permits from the Health Ministry, with approved manufacturing regulations, quality standards, and patient information sheets, and must report every single use and adverse reaction to Roszdravnadzor, the national health watchdog.

This is one of the first dedicated regulatory frameworks anywhere for fully personalized, point-of-care biotech manufacturing - essentially hospital-based production of bespoke medicines. For pharmacy students, it previews a future where the pharmacist's role may extend into on-site biotech compounding under strict quality systems. Compare this with how gene and cell therapies are regulated in India, the EU, and the US, and you can see different national philosophies emerging for advanced therapy medicinal products.

FDA approves Mirum's Atebrioz for rare bone disorder FOP

The US FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib), a once-daily oral ALK2 blocker, for patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP) - a devastating genetic disorder in which bone progressively forms in muscles, tendons, and ligaments, gradually locking the body in a second skeleton. Mirum plans an October launch, with pricing to be announced.

FOP is an ultra-rare disease with historically almost no treatment options, so any approved therapy is a landmark for patients. The mechanism is elegant pharmacology: FOP is driven by overactive ACVR1/ALK2 signaling in the BMP pathway, and Atebrioz directly blocks that receptor. For students, this is a clean illustration of target-based drug design - from genetic insight (ACVR1 mutations) to a druggable kinase target to an oral small molecule - and of how orphan-drug incentives make development viable for tiny patient populations.

DBT funds 200+ nanomedicine projects worth Rs 174 crore

At the World Congress on Nanomedicine 2026, held at Vigyan Bhawan, New Delhi on September 27, the government announced that the Department of Biotechnology is funding more than 200 research and development projects in nanomedicine with a combined outlay of Rs 174 crore. The funded work spans targeted drug delivery systems, nano oral insulin, and nanobots for breast cancer treatment.

This is a strong signal of where Indian pharmaceutical research is heading: nanoformulations that improve bioavailability, target drugs to diseased tissue, and reduce toxicity. Nano oral insulin, if it succeeds, would be a transformative alternative to injections for diabetes management. Pharmacy students should connect this funding push to their pharmaceutics syllabus - particle size, surface area, and drug release kinetics are exactly the concepts these projects are built on, and nanomedicine is rapidly becoming examinable, employable science.

Conclusion

Today's news falls into two clear clusters, and both point in the same direction: pharmacy is moving from one-size-fits-all medicines toward tightly controlled, precisely targeted therapy. The first cluster is regulatory tightening - India's CDSCO reviewing the framework for narcotic-containing drugs, and Russia formalizing rules for personalized biotech drugs. Both are regulators racing to keep pace with science: one closing loopholes that enable drug diversion, the other building guardrails for hospital-made, patient-specific medicines. The lesson for students is that regulation is not a static subject in a textbook - it evolves in real time alongside the technologies it governs, and pharmacists are the professionals who implement it.

The second cluster is the advanced-therapy wave: China's in vivo CAR-T IASO206, India's Rs 174 crore nanomedicine push, and the FDA's approval of Atebrioz for FOP. Whether it is engineering immune cells inside the body, delivering insulin in nanoparticles, or blocking a rogue bone-forming receptor with an oral pill, the common thread is precision - getting the right molecule to the right target with minimal collateral damage. For pharmacy students, the message is unmistakable: the future belongs to those who master both the molecular pharmacology and the delivery science. Stay curious about biologics, gene and cell therapy regulation, and novel drug delivery systems - they are no longer electives on the horizon; they are today's headlines.

References

  1. The Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cdsco-steps-up-scrutiny-of-pharma-drugs-containing-narcotic-substances/articleshow/134525250.cms
  2. NovaLead Pharma (press release) https://www.firstindia.co.in/news/press-releases/novaleads-patented-repurposed-drug-receives-approval-from-cdsco-for-the-treatment-of-diabetic-foot-ulcer-dfu-for-india-market
  3. Medical Dialogues https://medicaldialogues.in/news/industry/pharma/sanofi-india-faces-rs-2374-crore-gst-demand-over-alleged-excess-itc-claim-for-fy23-180108
  4. PR Newswire (IASO Bio) https://en.prnasia.com/story/549650-0.shtml
  5. ExpoPharmTech https://expopharmtech.com/articles/rules-for-individual-biotechnological-drug-circulation-approved-in-russia/
  6. ETPharma (Reuters) https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/us-fda-approves-mirums-drug-for-rare-bone-disorder/134529818
  7. Nation Press https://www.nationpress.com/national/dbt-funds-200-nanomedicine-projects

← All daily news